NEW YORK (GenomeWeb News) – Atossa Genetics on Thursday priced its initial public offering of 800,000 shares at $5 per share, raising gross proceeds of $4 million.

The Seattle-based firm granted its underwriter a 45-day option to purchase up to 120,000 shares to cover any overallotments. Atossa began trading on the Nasdaq Capital Market on Thursday under ticker symbol "ATOS." Its shares closed down 4 percent on Thursday at $4.80.

Dawson James Securities is the sole book-running manager on the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.